Scholars@Duke
Jonathan Paul Piccini Sr.

Jonathan Paul Piccini Sr.

Ursula Geller Distinguished Professor of Research in Cardiovascular Diseases
Medicine, Cardiology
jonathan.piccini@duke.edu
Duke Box 31115, Durham, NC 27710
Dept of Medicine, Durham, NC 27710

Scholarly Works - Conferences

Abstract 14106: The Efficacy of Sodium Glucose Co-transporter 2 Inhibitors in Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Conference Circulation · November 17, 2020 Background: Atrial Fibrillation (AF) is common in patients with Type 2 diabetes mellitus and it is associated with adverse outcomes. The impact of SGLT-2 inhibitors on incident AF and cardiovascular o ... Full text Cite

Machine learning does not improve upon traditional regression in predicting outcomes in atrial fibrillation: an analysis of the ORBIT-AF and GARFIELD-AF registries.

Conference Europace · November 1, 2020 AIMS: Prediction models for outcomes in atrial fibrillation (AF) are used to guide treatment. While regression models have been the analytic standard for prediction modelling, machine learning (ML) has been promoted as a potentially superior methodology. W ... Full text Link to item Cite

PREDICTORS OF FFR UNDERUTILIZATION

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 24, 2020 Link to item Cite

The Prognostic Value of Diastolic and Systolic Mechanical Left Ventricular Dyssynchrony Among Patients With Coronary Heart Disease.

Conference JACC Cardiovasc Imaging · July 2019 OBJECTIVES: The goal of this study was to examine whether diastolic dyssynchrony, measured by using gated single-photon emission computed tomography (GSPECT) myocardial perfusion imaging (MPI) in patients with coronary artery disease (CAD), is independentl ... Full text Link to item Cite

Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.

Conference J Am Heart Assoc · August 7, 2018 Background There is concern that selective serotonin reuptake inhibitors ( SSRI s) substantially increase bleeding risk in patients taking anticoagulants. Methods and Results We studied 737 patients taking SSRI s in the ROCKET AF (Rivaroxaban Once Daily Or ... Full text Link to item Cite

Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).

Conference Am J Cardiol · August 15, 2017 Non-dihydropyridine calcium channel blockers (non-DHP CCBs) possess combined P-glycoprotein and moderate CYP3A4 inhibition, which may lead to increased exposure of medications that are substrates for these metabolic pathways, such as rivaroxaban. We evalua ... Full text Link to item Cite

Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure: analysis of the ICD Registry and ADHERE.

Conference Circ Heart Fail · November 2014 BACKGROUND: Cardiac resynchronization therapy with defibrillator (CRT-D) reduces morbidity and mortality among selected patients with heart failure in clinical trials. The effectiveness of this therapy in clinical practice has not been well studied. METHOD ... Full text Link to item Cite

Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: Results from the ROCKET AF trial

Conference Journal of the American Heart Association · January 1, 2014 Background: Time in therapeutic range (TTR) is a standard quality measure of the use of warfarin. We assessed the relative effects of rivaroxaban versus warfarin at the level of trial center TTR (cTTR) since such analysis preserves randomized comparisons. ... Full text Cite